Search





Search





Biodexa Announces Partnership With Syngene To Manufacture Mtx240 Gmp Clinical Trial Supplies

ReutersApr 2, 2026 1:39 PM

April 2 (Reuters) - Biodexa Pharmaceuticals PLC 5MPy.F:

BIODEXA ANNOUNCES PARTNERSHIP WITH SYNGENE TO MANUFACTURE MTX240 GMP CLINICAL TRIAL SUPPLIES
BIODEXA PHARMACEUTICALS PLC - TO FILE IND AND INITIATE PHASE 1B/2A MTX240 STUDY BY YEAR-END

Further company coverage: [5MPy.F]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Nike Stock Falls Below 50 Dollars Is It Still a Good Investment?

TradingKey - For much of early 2026, Nike (NKE) was under significant selling pressure, resulting in an accelerated selloff following its fiscal Q3 report, which resulted in the stock price being pushed below $50.

Why Is IBM Seeking to Partner with Arm? Can This Drive IBM Earnings Growth?

TradingKey - On April 2, 2026, IBM and Arm announced a strategic partnership. The two parties will develop "dual-architecture hardware" to help enterprises run AI and data-intensive workloads with greater flexibility, reliability, and security.

WTI Oil Price Forecast: Trump Personally Opened the Path to Above $120.00

TradingKey - WTI prices continued to surge today as the market reprices Middle East risk.

Trump National Address ‘About-Face,’ Bitcoin Slumps Back to $66,000

Trump’s major reversal on Iran sparked a nearly 3% drop in Bitcoin, with the upcoming non-farm payroll data becoming a key focus.

Amazon Talks to Acquire Globalstar: Can $9 Billion Deal Challenge SpaceX Starlink?

TradingKey - During after-hours trading on April 1, 2026, shares of satellite communications company Globalstar (GSAT) surged 24%, with its market capitalization briefly approaching $9 billion. The rally was triggered by an exclusive report from the Financial Times stating that e-commerce giant Amaz

Tradingkey

KeyAI

